Business Wire

Dataiku Raises $101 Million Series C to Transform and Democratize Enterprise AI Globally

Share

Dataiku Inc., one of the world’s leading enterprise data science and machine learning platforms, today announced a $101 million Series C funding round led by ICONIQ Capital and supported by Alven Capital, Battery Ventures, Dawn Capital, and FirstMark Capital. This announcement follows the company’s $28 million Series B in September 2017 and the release of Dataiku 5 in September 2018.

Since its founding in 2013, Dataiku has focused on the vision of democratized data science as the key to uninhibited possibilities instead of restricted technologies reserved for the elite few. Today, Dataiku provides a platform that enables enterprises to fundamentally transform their business - global leaders use it to build AI that optimizes marketing budget, enables maintenance services, anticipate market trends or detects fraud, and more.

“We’re very excited about what this latest funding round represents - it’s a confirmation of our vision to build and deliver the missing block for the modern enterprise: the platform where you build you own AI,” said Florian Douetteau, CEO of Dataiku. “We have always believed that all jobs are being reshaped by data and that this transformation is made possible through education, access, and collaboration. Dataiku will continue to enable all of these things.”

With the onset of the age of AI, and with the latest round of funding, Dataiku will only accelerate this execution of large-scale data democratization within the enterprise. In a world with constantly evolving technology and tools, Dataiku has remained steadfast in its vision for the future and will continue to bring stability, security, and reliability for companies trying to navigate their own journeys in the age of Enterprise AI.

“Dataiku solves a real and rapidly growing market need for businesses to extract measurable value out of massive and disparate streams of data,” said Adar Zango, Principal at ICONIQ Capital. “Importantly, the platform achieves this with a highly differentiated approach that democratizes data at scale and engages a variety of personalities in a collaborative fashion: data scientists, data engineers, data analysts and business analysts are able to work together on a single platform to quickly derive insights. Large and sophisticated users across all industries have emphasized the exceptional product and this uniquely collaborative approach and we are genuinely thrilled for the opportunity ahead.”

As today’s discussions surrounding AI shift, Dataiku will also continue (through its product offering and initiatives) to forward the awareness and action surrounding topics like diversity and trust in the field, which are increasingly points of contention and oversight that need to be addressed. In this respect, Dataiku will work to grow its vision of data education for all by expanding its academic and non-profit programs as well as EGG conferences.

With this latest funding round, Dataiku (who was named by Forbes among the “Best Big Data Companies And CEOs To Work For In 2018”) plans to double its current staff of 200 among its headquarters in New York City and offices in Paris and London as well as new offices in Sydney and Singapore. Dataiku will also accelerate the addition of new product features and work to expand its network of technology partners.

Dataiku has more than 200 global customers across retail, e-commerce, health care, finance, transportation, the public sector, manufacturing, pharmaceuticals, and more (including General Electric, Sephora, Unilever, KUKA, FOX, and BNP Paribas).

To learn more visit: www.dataiku.com

*Gartner, Inc., “Magic Quadrant for Data Science and Machine-Learning Platforms,” 22 February, 2018. This report was formerly titled Magic Quadrant for Data Science Platforms.

About Dataiku

Dataiku is the centralized data platform that moves businesses along their data journey from analytics at scale to enterprise AI. By providing a common ground for data experts and explorers, a repository of best practices, shortcuts to machine learning and AI deployment/management, and a centralized, controlled environment, Dataiku is the catalyst for data-powered companies.

About ICONIQ Capital

ICONIQ Capital is a privately-held investment firm that serves some of the world’s most influential families and organizations. ICONIQ provides financial advisory and family office services, and manages direct investments across asset classes, with specific focus on technology growth equity, venture capital, middle market buyout and real estate.

About Dawn Capital

Established in 2007, Dawn Capital is the largest VC fund dedicated to B2B software and B2B fintech start-ups across Europe. Dawn invests from Series A onwards, backing companies that develop world leading offerings with unbeatable economics. Currently investing out of its third fund of $235 million, Dawn offers ambitious founders operational and financial support to deliver exceptional value growth. Dawn’s portfolio companies include Mimecast (NASDAQ: MIME with $2.5BN market cap), iZettle (sold to PayPal for $2.2BN cash), Collibra, Showpad and Automile, with many others looking to join their rank.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact for Dataiku :
Addison Huegel
ahuegel@elevatorpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye